We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Exelixis (EXEL) Outperforms Industry in 1H22: What Lies Ahead?
Read MoreHide Full Article
Exelixis (EXEL - Free Report) has had a good run so far this year. In fact, it is one of the few biotech stocks that has outperformed the industry in this time frame.
Shares have gained 18% in the year so far against the industry’s decline of 22.6%.
Image Source: Zacks Investment Research
Exelixis’ lead drug Cabometyx, approved for treating patients with advanced renal cell carcinoma (RCC) and patients with hepatocellular carcinoma (HCC) who have been previously treated with Nexavar, aids the company’s momentum amid stiff competition.
In particular, the approval of Cabometyx for patients with advanced RCC as a first-line treatment in combination with Bristol Myers’ (BMY - Free Report) Opdivo (nivolumab) has fuelled sales of the drug.
Bristol-Myers’ Opdivo is one of the leading revenue generators of the company and is approved for various oncology indications.
Cabometyx is also approved for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC).
The pipeline progress has been impressive as far as the company strives to develop its portfolio beyond lead drug Cabometyx.
Other candidates in Exelixis’ pipeline include XL092, a next-generation oral tyrosine kinase inhibitor (TKI); XB002, an antibody drug conjugate (ADC) that targets tissue factor (TF); XL102, a potent, selective and orally bioavailable covalent inhibitor of cyclin-dependent kinase 7 (CDK7); and XL114, a novel anti-cancer compound that inhibits the CARD11-BCL10-MALT1 (CBM) complex.
The company recently initiated STELLAR-303, a phase III study evaluating XL092 in combination with Roche’s Tecentriq (atezolizumab) versus Stivarga (regorafenib) in patients with metastatic colorectal cancer (CRC) that is not microsatellite instability-high or mismatch repair-deficient, who have progressed after or are intolerant to the standard of care therapy. XL092 is a next-generation tyrosine kinase inhibitor (TKI) in development for multiple advanced tumor types.
Exelixis also entered into an option and license agreement with BioInvent International AB to develop novel antibody-based immuno-oncology therapies. The company earlier initiated the dose-escalation stage of the first-in-human phase I study of investigational candidate XL114 as a monotherapy in patients with non-Hodgkin’s lymphoma (NHL) who have received prior standard therapies.
The successful development of these candidates will broaden its portfolio and reduce its dependence on Cabometyx.
Competition is stiff in the RCC space, and capturing additional market share might become tough for Exelixis.
Merck’s (MRK - Free Report) Keytruda, in combination with Pfizer’s (PFE - Free Report) Inlyta, is also indicated for the first-line treatment of patients with advanced RCC.
Merck’s Keytruda, an anti-PD-1 therapy, is approved for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy or nephrectomy and resection of metastatic lesions.
Pfizer’s Inlyta has shown strong performance, driven by continued adoption in the United States and Europe. PFE’s older drug Sutent is also approved for advanced RCC.
Image: Bigstock
Exelixis (EXEL) Outperforms Industry in 1H22: What Lies Ahead?
Exelixis (EXEL - Free Report) has had a good run so far this year. In fact, it is one of the few biotech stocks that has outperformed the industry in this time frame.
Shares have gained 18% in the year so far against the industry’s decline of 22.6%.
Image Source: Zacks Investment Research
Exelixis’ lead drug Cabometyx, approved for treating patients with advanced renal cell carcinoma (RCC) and patients with hepatocellular carcinoma (HCC) who have been previously treated with Nexavar, aids the company’s momentum amid stiff competition.
In particular, the approval of Cabometyx for patients with advanced RCC as a first-line treatment in combination with Bristol Myers’ (BMY - Free Report) Opdivo (nivolumab) has fuelled sales of the drug.
Bristol-Myers’ Opdivo is one of the leading revenue generators of the company and is approved for various oncology indications.
Cabometyx is also approved for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC).
The pipeline progress has been impressive as far as the company strives to develop its portfolio beyond lead drug Cabometyx.
Other candidates in Exelixis’ pipeline include XL092, a next-generation oral tyrosine kinase inhibitor (TKI); XB002, an antibody drug conjugate (ADC) that targets tissue factor (TF); XL102, a potent, selective and orally bioavailable covalent inhibitor of cyclin-dependent kinase 7 (CDK7); and XL114, a novel anti-cancer compound that inhibits the CARD11-BCL10-MALT1 (CBM) complex.
The company recently initiated STELLAR-303, a phase III study evaluating XL092 in combination with Roche’s Tecentriq (atezolizumab) versus Stivarga (regorafenib) in patients with metastatic colorectal cancer (CRC) that is not microsatellite instability-high or mismatch repair-deficient, who have progressed after or are intolerant to the standard of care therapy. XL092 is a next-generation tyrosine kinase inhibitor (TKI) in development for multiple advanced tumor types.
Exelixis also entered into an option and license agreement with BioInvent International AB to develop novel antibody-based immuno-oncology therapies.
The company earlier initiated the dose-escalation stage of the first-in-human phase I study of investigational candidate XL114 as a monotherapy in patients with non-Hodgkin’s lymphoma (NHL) who have received prior standard therapies.
The successful development of these candidates will broaden its portfolio and reduce its dependence on Cabometyx.
Competition is stiff in the RCC space, and capturing additional market share might become tough for Exelixis.
Merck’s (MRK - Free Report) Keytruda, in combination with Pfizer’s (PFE - Free Report) Inlyta, is also indicated for the first-line treatment of patients with advanced RCC.
Merck’s Keytruda, an anti-PD-1 therapy, is approved for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy or nephrectomy and resection of metastatic lesions.
Pfizer’s Inlyta has shown strong performance, driven by continued adoption in the United States and Europe. PFE’s older drug Sutent is also approved for advanced RCC.
Exelixis currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.